Avocado at breakfast: a secret weapon for blood sugar and fullness?

NCT ID NCT06818032

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether eating avocado with a breakfast of bread and jam can improve how the body handles blood sugar and signals hunger or fullness afterward. Thirty healthy adults will compare three different breakfasts — one with avocado, one with added fat and fiber to mimic avocado, and a plain bread-and-jam meal — and have their blood drawn over several hours. The goal is to see if avocado offers unique benefits for glucose control and appetite regulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
avocado
What this could lead to
If avocado helps control blood sugar and appetite after meals, it could point toward simple dietary tweaks for better metabolic health.
What could go wrong
This is a small, short-term trial in healthy adults — results may not apply to people with diabetes or other conditions, and any effects might be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Mar 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biological sex males or females * Age 21 to 65 years * BMI between 18.5 and 34.9 kg/m2 Exclusion Criteria: * Actively pregnant or lactating women * Diagnosis of prediabetes or diabetes (fasting glucose \>100 mg/dL) * Current diagnosis of uncontrolled hypertension (systolic BP: \>160 mmHg, diastolic BP: \>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month * Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \>200 mg/dL, fasting triglycerides \>200 mg/dL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month * Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus) * History of bariatric or certain other surgeries related to weight control * Any medication used to lower blood glucose/antidiabetic medications \[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\] as well as medications affecting weight, appetite/hunger or gut motility. * Smoking or use of other tobacco products (during 6 months prior to the start of the study) * Antibiotic use during the intervention or for 3 weeks prior to any treatment period * History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets) * Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence * Body weight loss of \>10% within the last 6 months prior to study start * Unable or unwilling to give informed consent or communicate with study staff * Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion) * Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol * Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Research Center, University of Vermont Medical Center

    Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.